Xlife Sciences Forecast, price target & analysts
Xlife Sciences Target price 2026 - Analyst rating & recommendation
Xlife Sciences Classifications & Recommendation:
Xlife Sciences Price Target
| Target Price | CHF69.36 |
| Price | CHF24.70 |
| Potential |
180.81%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Xlife Sciences 2027 .
The average Xlife Sciences target price is CHF69.36.
This is
180.81%
register free of charge
CHF71.40
189.07%
register free of charge
CHF68.68
178.06%
register free of charge
|
|
| A rating was issued by 5 analysts: 4 Analysts recommend Xlife Sciences to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Xlife Sciences stock has an average upside potential 2027 of
180.81%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 0.83 | 2.15 |
| 16.16% | 158.43% | |
| EBITDA Margin | -400.00% | -322.49% |
| 6.60% | 19.38% | |
| Net Margin | 4,130.12% | -173.52% |
| 174.79% | 104.20% |
2 Analysts have issued a sales forecast Xlife Sciences 2025 . The average Xlife Sciences sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF830k | 16.16% |
|---|---|---|
| 2025 |
CHF2.1m
158.43%
Unlock
|
|
2 Analysts have issued an Xlife Sciences EBITDA forecast 2025. The average Xlife Sciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF-3.3m | 21.70% |
|---|---|---|
| 2025 |
CHF-6.9m
108.36%
Unlock
|
|
EBITDA Margin
| 2024 | -400.00% | 6.60% |
|---|---|---|
| 2025 |
-322.49%
19.38%
Unlock
|
|
2 Xlife Sciences Analysts have issued a net profit forecast 2025. The average Xlife Sciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF34.3m | 130.38% |
|---|---|---|
| 2025 |
CHF-3.7m
110.85%
Unlock
|
|
Net Margin
| 2024 | 4,130.12% | 174.79% |
|---|---|---|
| 2025 |
-173.52%
104.20%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 4.67 | -0.65 |
| 124.52% | 113.92% | |
| P/E | negative | |
| EV/Sales | 93.93 |
2 Analysts have issued a Xlife Sciences forecast for earnings per share. The average Xlife Sciences EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF4.67 | 124.52% |
|---|---|---|
| 2025 |
CHF-0.65
113.92%
Unlock
|
|
P/E ratio
| Current | 4.62 | 46.20% |
|---|---|---|
| 2025 |
-38.09
925.03%
Unlock
|
|
Based on analysts' sales estimates for 2025, the Xlife Sciences stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 239.87 | 19.80% |
|---|---|---|
| 2025 |
93.93
60.84%
Unlock
|
|
P/S ratio
| Current | 169.59 | 17.52% |
|---|---|---|
| 2025 |
66.41
60.84%
Unlock
|
|
Current Xlife Sciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ALPHAVALUE |
Locked
➜
Locked
|
Locked | Sep 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
ALPHAVALUE:
Locked
➜
Locked
|
Sep 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
